Announcements Trials
Browse Landscape

Phase

Phase 2 76Phase 1 29Phase 1/2 26Phase 3 7Phase 4 3Phase NA 2Phase EARLY_PHASE1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Dermatologic 2Tumor-Agnostic 1CNS 1

Conditions

Melanoma 2Skin Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 10pembrolizumab 6Ipilimumab 6Niacinamide 3Magnetic Resonance Spectroscopy 3Itraconazole 3Cyclophosphamide 3Biopsy 3resiquimod 2encorafenib 2durvalumab 2calcipotriene 2binimetinib 2aldesleukin 2Radiotherapy 2Oncolytic Virotherapy 2Niacin 2MART-1 Antigen 2Interleukin-2 2Imiquimod 2HhAntag691 2Fluorouracil 2Ascorbic Acid 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × aldesleukin × Dermatologic × Clear all
NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
11 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT00276835 2015-04-10

Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer

Northwestern University

Phase EARLY_PHASE1 Completed
15 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡